Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Arcus Biosciences, Inc.
RCUS
NYSE·Healthcare·Biotechnology·Mkt cap $2.9B
$29.95
▲ +3.54%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$8.03 - $31.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 236.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual-mechanism approach combining checkpoint inhibition with metabolic pathway targeting for enhanced anti-tumor immunity
- Strategic partnerships with AstraZeneca and other leading pharmaceutical companies providing development resources and market access
- Proprietary small-molecule and monoclonal antibody platform technology enabling multiple therapeutic modalities
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Revenue decline expected
Advancement of Domvanalimab Phase 3 trial in combination with Imfinzi for unresectable Stage III NSCLC
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+26.0% over 3m
Quality
Excellent
High-growth business (67% revenue growth, 97% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying RCUS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of -$1.02 vs -$0.92 consensus (-10.9% surprise). Revenue of $17.0M vs $29.5M expected (-42.3%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-10.9%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
-16%
-81%
+310%
-46%
+27%
-39%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$39.0M
$48.0M
$26.0M
$28.0M
$160.0M
$26.0M
$33.0M
$17.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-752.9%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
29%
Sell
0%
Median Price Target
$35.00
▲ +16.9% vs $29.95
Latest: Truist · $35.00 · May 18, 2026
3 analysts covering